Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase
The preferred route of administration for an injected therapeutic agent is subcutaneous (SC), but SC injections are generally limited to no more than 1-2 mL in volume, representing a major challenge, especially for large protein biologics.


Pharmaceutical Technology


Bioavailability of large co-injected proteins


Figure 5: Pharmacokinetic parameters of a pegylated cytokine and a monoclonal antibody that were co-injected with either placebo or with rHuPH20: (a) bioavailability (area under concentration versus time curve [AUC] as a percentage of intravenous [IV]) and (b) Cmax (the maximum concentration of a drug in the systemic circulation after dosing). CMP is counts/min. (FIGURES: HALOZYME THERAPEUTICS)
The available data indicate that when co-injected with rHuPH20, molecules should be dispersed more thoroughly. This situation should lead to increased exposure to capillary beds and lymphatics and greater bioavailability. This approach was evaluated in a rodent model using a 31-kDa pegylated cytokine (peginterferon alfa 2b) and a 149-kDa monoclonal antibody (infliximab) (38). As shown in Figures 5a and 5b, respectively, local co-injection with rHuPH20 increased the absolute bioavailability and Cmax (the maximum concentration of a drug in the systemic circulation after dosing) of the cytokine (bioavailability: 61% was increased to 108%,p (p value) <0.001; Cmax: 61,782 to 121,750 CPM (counts per minute)/g, p <0.0003), and the antibody (bioavailability: 59% was increased to 94%, p <0.00001; Cmax: 531,866 to 875,369 CPM/g, p <0.00002). rHuPH20 is clearly able to improve the pharmacokinetic profiles of co-injected drugs compared with the pharmacokinetics typically observed following IV administration. This improved profile results in increased bioavailability. As large drugs typically access the systemic circulation through the lymphatic vessels, it appears that rHuPH20 may be exerting an effect on bulk-liquid flow through the draining lymphatics.

Conclusion

For large protein biologics such as monoclonal antibodies, volume and bioavailability constraints must be overcome before subcutaneous injections can mirror intravenous (IV)-like dosing regimens. While "spreading factors" have been exploited clinically for many years, the problems associated with such animal-derived agents have limited their use, particularly in the chronic setting. The discovery of the human hyaluronidase gene family and the molecular engineering of a purified soluble human rDNA-derived PH-20 hyaluronidase enzyme (rHuPH20), however, have propelled the clinical development of an enzyme-mediated drug-delivery system. Data indicate that molecules as large as 200 nm in diameter were readily dispersed when co-injected with rHuPH20 and resulted in markedly reduced tissue distortion. The pharmacokinetic profiles of molecules co-injected with rHuPH20 showed a higher Cmax (the maximum concentration of a drug in the systematic circulation after dosing) and earlier Tmax (the time to Cmax) than those co-injected with carrier controls. Systemic bioavailability of large molecules typically absorbed by the lymphatic route was significantly increased with rHuPH20 co-injection, leading to profiles approaching those achieved with IV dosing. rHuPH20 represents a broad platform technology for potentially altering the dosing regimens and bioavailability of many agents, including biotechnology-derived proteins.

Acknowledgment

The author would like to acknowledge the work completed by Halozyme Therapeutics' research staff, especially Gregory Frost, PhD, who is chief scientific officer, director, and vice-president of Halozyme Therapeutics.

Michael F. Haller, PhD, is vice-president of alliance management and portfolio development at Halozyme Therapeutics, 11388 Sorrento Valley Road, San Diego CA 92121, tel: 858.704.8211,

Submitted: July 19, 2007; Accepted Aug. 8, 2007.

References

1. D. Gilbert and & D. Cothran, "SC versus IV Delivery: Reducing Costs while Increasing Patient Satisfaction," Hematology & Oncology News & Issues, Dec. 25–27, 2005.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here